Open AccessOutcomes of patients with chronic plaque psoriasis and hidradenitis suppurativa on biologic therapy during the Covid‐19 pandemic: A UK dermatology tertiary centre experience
Author(s) -
Khan S.,
Karponis D.,
Wali G.
Publication year - 2021
Publication title -
skin health and disease
Language(s) - English
Resource type - Journals
ISSN - 2690-442X
DOI - 10.1002/ski2.54
Subject(s) - hidradenitis suppurativa , medicine , psoriasis , dermatology , pandemic , covid-19 , retrospective cohort study , plaque psoriasis , adalimumab , tertiary care , cohort , surgery , disease , pathology , infectious disease (medical specialty) , outbreak
Retrospective review data from 183 patients with psoriasis and/or hidradenitis suppurativa from a UK tertiary dermatology centre, suggests biologic therapy does not confer a significant increased risk of contracting severe Covid‐19 in this cohort. This is in line with a growing body of evidence which indicates that it is safe to continue using biologic therapies during the pandemic.